

Integrated Analysis of Genomic and Genome-Wide Association Studies Identified Candidate Genes for Nutrigenetic Studies in Flavonoids and Vascular Health: Path to Precision Nutrition for (Poly)phenols

Tatjana Ruskovska¹, Filip Postolov¹ and Dragan Milenkovic²

¹Faculty of Medical Sciences, Goce Delcev University, 2000 Stip, North Macedonia

²Plants for Human Health Institute, Department of Food Bioprocessing & Nutrition Sciences, NC State University, Kannapolis, NC 28081, USA



NC STATE
UNIVERSITY

PURPOSE

Flavonoids exert vasculoprotective effects in humans, but interindividual variability in their action has also been reported. This study aims to identify genes that are associated with vascular health effects of flavonoids and whose polymorphisms could explain interindividual variability in response to their intake.

METHODS

- Systematic literature search** was conducted to identify human intervention studies with flavonoids that analysed global gene expression and demonstrated **at least one positive effect on vascular function**. Differentially expressed genes (**DEGs**) were extracted from these studies. Upstream Regulators (**URs**) for each set of DEGs were obtained through **Qiagen-IPA tool**.
- Genes associated with vascular dysfunction** were independently identified from genome-wide association studies (**GWAS**), focusing on traits such as **hypertension, atherosclerosis, and arterial stiffness**.
- Integrative Analysis** using *InteractiVenn* was then performed by comparing DEGs from intervention studies with GWAS-derived genes to identify **overlapping candidate genes relevant to flavonoid-mediated vascular effects**.
- Pathway Enrichment Analysis (Gene Trail 3.2.)** and **Functional Analysis** we aimed to select **top priority candidate genes**. For these, we used the National Center for Biotechnology Information (NCBI) *Variation Viewer* to identify high-frequency variants and queried *PharmGKB* for pharmacogenomic relevance.


Abbreviations: DEGs = differentially expressed genes; URs = upstream regulators; GWAS = genome-wide association studies. DOI:10.3390/nu16091362

RESULTS


By extracting data from the 5 eligible human intervention studies with flavonoids, we obtained **5807 differentially expressed genes (DEGs)**. The number of identified upstream regulators (**URs**) varied across the studies, from **227 to 1407**. The search of the **GWAS Catalog** revealed **493 genes associated with vascular dysfunction**. An **integrative analysis** of the transcriptomic data with GWAS genes identified **106 candidate DEGs** and **42 candidate URs**, while subsequent **functional analyses** and a search of the literature identified **20 top priority candidate genes**:

ALDH2, APOE, CAPZA1, CYP11B2, GNA13, IL6, IRF5, LDLR, LPL, LSP1, MKNK1, MMP3, MTHFR, MYO6, NCR3, PPARG, SARM1, TCF20, TCF7L2, and TNF.

Through the **Variation Viewer** database we identified their **variant types, molecular consequences, most severe clinical significances, and top 10 genetic variants with highest frequencies**, while PharmGKB revealed multiple variants that have already been shown to have specific **pharmacologic relevance**.



PAPER	STUDY POPUALTION	BIOACTIVES	OUTCOMES
1	Healthy, middle-aged, moderately overweight men	Hesperidin	↓ DBP
2	Non-obese, healthy male smokers, smoking 10 and more cigarettes per day for at least 5 years	Monomeric and oligomeric flavanols from grape seeds	Improved Vascular Health Index
3	Healthy male volunteers	Wild blueberry anthocyanins	↑ flow-mediated vasodilatation ↓ 24 h SBP
4	Healthy middle-aged men	Cocoa flavanols	↑ Flow-Mediated Vasodilatation ↓ SBP and DBP ↓ Pulse Wave Velocity
5	Healthy, non-smoking women, 3 to 10 years after menopause	Grapefruit juice flavanones	↓ Carotid–Femoral Pulse Wave Velocity



CONCLUSION

In conclusion, we performed an integrated bioinformatic analysis with large-scale GWAS and transcriptomic data to generate a refined list of candidate causal genes for interindividual variability in response to flavonoid intake. These results should serve as an important resource, facilitating the focusing of nutrigenetic research in the field of plant food bioactives to identify gene variants associated with a better health response to these bioactives, and therefore, build a foundation for precision nutrition research in the field of (poly)phenols.

Canonical Pathways	Number of Hits	Genes
Pathways directly involved in vascular dysfunction		
VEGFA-VEGFR2 Signaling Pathway *	6	CSK, MKNK1, MYO6, PTPRJ, SMARCA2, TNXB
Regulation of actin cytoskeleton **	4	BRK1, CSK, GNA13, SOS2
Adherens junction	3	PTPRJ, TCF7L2, YES1
Angiotensin Like Protein 8 Regulatory Pathway *	3	LPL, PRKAG2, SOS2
ECM-receptor interaction	3	NPNT, TNXB, VTN
Focal adhesion	3	SOS2, TNXB, VTN
Apelin signaling pathway	2	GNA13, PRKAG2
Cholesterol metabolism	2	LDLR, LPL
Composition of Lipid Particles *	2	LDLR, LPL
Fluid shear stress and atherosclerosis	2	BMPRI1, GSTA4
Glycerolipid metabolism	2	ALDH2, LPL
Metabolic pathway of LDL, HDL and TG, including diseases *	2	LDLR, LPL
Platelet activation	2	GNA13, LYN
Statin Pathway *	2	LDLR, LPL
Pathways involved in inflammation		
Chemokine signaling pathway **	3	CSK, LYN, SOS2
Cytokine-cytokine receptor interaction	3	BMPRI1, GDF10, LTB
TNF-kappa B signaling pathway **	3	LTB, LYN, TAB2
Regulation of toll-like receptor signalling pathway *	3	IRF5, SARM1, TAB2
B cell receptor signaling pathway	2	LYN, SOS2
Interleukin-11 Signaling Pathway *	2	FES, YES1
Natural killer cell mediated cytotoxicity	2	NCR3, SOS2
Structural Pathway of Interleukin 1 (IL-1) *	2	MKNK1, TAB2
TNF signaling pathway	2	DAB2IP, TAB2
Toll-like receptor signaling pathway **	2	IRF5, TAB2
Cell signaling pathways		
MAPK signaling pathway **	4	MKNK1, SOS2, STK3, TAB2
PI3K-Akt signaling pathway **	4	MCL1, SOS2, TNXB, VTN
EGF/EGFR Signaling Pathway *	3	CSK, SOS2, TWIST1
Insulin signaling pathway	3	MKNK1, PRKAG2, SOS2
Sterol Regulatory Element-Binding Proteins (SREBP) signalling *	3	LDLR, LPL, PRKAG2
cGMP-PKG signaling pathway	2	ATP2B1, GNA13
FoxO signaling pathway	2	PRKAG2, SOS2
Jak-STAT signaling pathway	2	MCL1, SOS2
Phospholipase D signaling pathway	2	GNA13, SOS2
Wnt Signaling Pathway and Pluripotency *	2	LDLR, TCF7L2
Antioxidant protection		
NRF2 pathway *	2	GSTA4, SLC39A8

Gene	Variant Type (Number)	Molecular Consequences (Number)	Most Severe Clinical Significance (Number)	Number of Associations with Pharmacological Significance	10 Variants with Highest Frequencies			
					Variant ID	Molecular Consequences	Alleles	Frequency
ALDH2	single nucleotide variant (172)	missense variant (1) synonymous variant (133) deletion (2) insertion (2) indel (2)	pathogenic (1)	9	r5728651	intronic variant	C>A,G	0.48704
					r6489793	3 prime UTR variant	T>G	0.48704
					r2106697	not specified	T>A,C,G	0.48646
					r10774638	intronic variant	T>A,C	0.49312
					r886305	2 KB upstream variant	A,C,G,T	0.49124
					r5707939	intronic variant	A>G	0.419728
					r10774637	intronic variant	C,G,T	0.419129
					r9971942	not specified	C,T	0.410743
					r10774639	not specified	G,A,C,T	0.410743
					r11066028	intronic variant	A,C,G,T	0.372894
APOE	single nucleotide variant (8)	missense variant (5) synonymous variant (1) intronic variant (4) 3 prime UTR variant (1) 500 B downstream variant (1) 2 KB upstream variant (1) intronic variant	pathogenic (2) drug-response (2)	33	r455559	missense variant, intronic variant, synonymous variant	T>G	0.47845
					r445446	missense variant	C>G,T	0.375802
					r578450	variant	G>A	0.327276
					r452558	intronic variant	T>C	0.32659
					r57812	missense variant	C,T	0.0752099
					r578449	missense variant	G>A	0.068962
					r1881105	missense variant	A,C,G	0.0301518
					r587793	500 B downstream variant, 5 prime UTR variant, intronic variant	C,A,T	0.0139744
					r3013440	intronic variant	G,A	0.478435
					r5724494	intronic variant	A,G,T	0.478435
CAPZA1	single nucleotide variant (136)	missense variant (2) synonymous variant (2) deletion (1) nc transcript variant (1) 3 prime UTR variant (3) 5 prime UTR variant (1) 500 B downstream variant (2) 2 KB upstream variant (2) intronic variant	/	/	r1413520	intronic variant	G,A	0.478435
					r3101840	intronic variant	G,A,T	0.478435
					r2592336	intronic variant	G,A,T	0.478435
					r3013439	intronic variant	T,A,G	0.478435
					r12046229	intronic variant	T,A,C,G	0.478435
					r12046466	intronic variant	T,A,C	0.478435
					r12046208	intronic variant	C,T	0.435002
					r4524846	intronic variant	T,A,C,G	0.435002
					r30110702	intronic variant	C,T	0.485308
					r28615142	intronic variant	T,C	0.485227
CYP11B2	single nucleotide variant (86)	missense variant (9) synonymous variant (6) intronic variant (66) 500 B downstream variant (2) 2 KB upstream variant (5) intronic variant	pathogenic (1) benign (17)	5	r28586703	intronic variant	A,G	0.485226
					r13261040	intronic variant	A,C	0.479433
					r6421	intronic variant	T,C	0.460064
					r57021079	intronic variant	A,T	0.45607
					r80063072	intronic variant	A,G	0.45607
					r74838461	intronic variant	T,C	0.45607
					r28394055	intronic variant	C,T	0.445887
					r6420	intronic variant	G,A,C,T	0.445887
					r57021079	intronic variant	A,T	0.45607
					r80063072	intronic variant	A,G	0.45607

Declaration of Interest: The authors declare no conflicts of interest.